• In November 2022, Gilead Sciences, Inc. gained FDA approval for Vemlidy (tenofovir alafenamide) 25 mg tablets, expanding its usage to treat chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. This approval marked a significant advancement in providing a once-daily treatment option for this patient population.

• In April 2022, Lupin secured FDA approval for its tenofovir alafenamide tablets to address chronic hepatitis B virus infection. This approval underscores the growing options available for managing HBV infection, offering patients additional therapeutic choices to address their medical needs.

In this report, the Global Hepatitis Therapeutics Market has been segmented by Disease Type, Drug Class, Distribution Channel and Geography.

Global Hepatitis Therapeutics Market, Segmentation by Disease Type

The Global Hepatitis Therapeutics Market has been segmented by Disease Type into Hepatitis A, Hepatitis B, and Hepatitis C.

Hepatitis A

Hepatitis A represents about 10–15% of the global hepatitis therapeutics market. While often a self-limiting condition, severe cases—especially among the elderly or immunocompromised—require supportive care and antiviral treatment. Public health efforts during outbreaks further contribute to sporadic demand.

Hepatitis B

Hepatitis B leads the therapeutic segment with approximately 40–45% market share. The chronic nature of the disease and its high prevalence in regions like Asia and Africa drive consistent demand for antiviral drugs, including nucleoside analogs and immunoglobulin therapies.

Hepatitis C

Hepatitis C accounts for nearly 40–45% of the market and has experienced remarkable growth with the introduction of direct-acting antivirals (DAAs). These medications offer high cure rates, reduced treatment durations, and have gained rapid adoption across developed and developing markets alike.

Global Hepatitis Therapeutics Market, Segmentation by Drug Class

The Global Hepatitis Therapeutics Market has been segmented by Drug Class into Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) Inhibitors, Nucleotide Analog Reverse Transcriptase Inhibitors, Nucleotide Analog NS5B Polymerase Inhibitors, Multi Class Combination, and Others.

Interferon

Interferon therapies represent around 10–12% of the hepatitis therapeutics market. While their use has declined with the advent of direct-acting antivirals, they remain relevant in treating specific hepatitis B and C cases where alternative treatments are less effective or unavailable.

Monoclonal Antibody

Monoclonal antibodies contribute roughly 5–8% of the market and are under increasing investigation for their immunomodulatory potential. These targeted therapies are particularly promising in chronic hepatitis B research and development pipelines.

Non-structural Protein 5A (NS5A) Inhibitors

NS5A inhibitors hold a substantial 15–20% share and are integral to hepatitis C treatment. Known for their high antiviral potency and shortened treatment cycles, they are a cornerstone of modern combination therapies.

Nucleotide Analog Reverse Transcriptase Inhibitors (NRTIs)

NRTIs dominate the segment with an estimated 25–30% share, primarily used in the long-term suppression of hepatitis B virus. Their efficacy and widespread adoption have made them a standard of care in HBV management globally.

Nucleotide Analog NS5B Polymerase Inhibitors

NS5B polymerase inhibitors contribute about 10–12% of the market and are designed to inhibit viral replication in hepatitis C. Often used alongside NS5A inhibitors, they enhance treatment success rates and reduce resistance.

Multi-Class Combination

Multi-class combination therapies account for nearly 15–20% of the market, offering a strategic advantage in treating hepatitis C by combining drugs from different mechanisms to improve overall efficacy and shorten treatment durations.

Others

The Others category, covering about 5–8%, includes supportive medications, emerging antivirals, and pipeline drugs exploring novel targets to overcome viral resistance and enhance patient outcomes.

Global Hepatitis Therapeutics Market, Segmentation by Distribution Channel

The Global Hepatitis Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Others.

Hospital Pharmacies

Hospital pharmacies lead the hepatitis therapeutics market by distribution channel, accounting for approximately 45–50% of global sales. These institutions handle complex and acute hepatitis treatments, often involving injections, infusions, or advanced care for chronic liver conditions. Their integration with diagnostic and inpatient services drives consistent demand.

Drug Stores and Retail Pharmacies

Drug stores and retail pharmacies hold a significant 35–40% market share. They are crucial for dispensing oral antiviral medications used in the long-term treatment of hepatitis B and C. Convenience, accessibility, and routine prescription refills make them a popular choice for outpatients.

Others

Other distribution channels, including online pharmacies, mail-order services, and specialty clinics, contribute approximately 10–15% of the market. This segment is witnessing steady growth due to the expansion of digital health services, rising telemedicine adoption, and increased availability in remote and underserved areas.

Global Hepatitis Therapeutics Market, Segmentation by Geography

In this report, the Global Hepatitis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Global Hepatitis Therapeutics Market Share (%), by Geographical Region, 2024

North America

North America leads the global hepatitis therapeutics market with a share of around 35–40%. The region benefits from advanced healthcare infrastructure, widespread disease awareness, and strong reimbursement frameworks. The U.S., in particular, sees high uptake of novel antiviral therapies and maintains aggressive screening and treatment protocols.

Europe

Europe accounts for approximately 25–30% of the market, driven by government-supported healthcare systems and comprehensive screening initiatives. Nations like Germany, France, and the United Kingdom lead in hepatitis prevention and management through structured care pathways.

Asia Pacific

Asia Pacific contributes nearly 20–25% of global revenue and is one of the fastest-growing markets. High hepatitis prevalence, particularly in China and India, along with increasing healthcare investments and public awareness campaigns, are fueling regional demand.

Middle East & Africa

Middle East & Africa represent a modest share of 5–8%, but the region is experiencing steady growth due to rising hepatitis B and C incidence. Healthcare infrastructure improvements and government-led awareness programs are contributing to treatment expansion.

Latin America

Latin America holds about 5–7% of the global market. With growing focus on early diagnosis and expanding public healthcare coverage, countries such as Brazil and Mexico are seeing increased demand for hepatitis therapeutics.